<main class="html-publication" lang="en" role="main">
      

  <div class="publication-external">
    <ul class="organisation-logos">
        <li class="organisation-logos__logo">
          
<div class="gem-c-organisation-logo brand--department-of-health">
    <a class="gem-c-organisation-logo__container gem-c-organisation-logo__link gem-c-organisation-logo__crest gem-c-organisation-logo__crest--single-identity brand__border-color" href="/government/organisations/uk-health-security-agency">
      <span class="gem-c-organisation-logo__name">UK Health<br>Security<br>Agency</span>
</a>
</div>
        </li>
    </ul>
  </div>

  <header class="gem-c-inverse-header  gem-c-inverse-header--padding-top ">
    
  

<div class="gem-c-title gem-c-title--inverse govuk-!-margin-top-8 govuk-!-margin-bottom-0">
      <span class="govuk-caption-xl gem-c-title__context">
    Guidance
  </span>


  <h1 class="gem-c-title__text govuk-heading-xl">
    Diphtheria anti-toxin: clinical guidance (issued May 2022)
  </h1>
</div>
  <p class="publication-header__last-changed">Updated 4 May 2022</p>

  </header>



<div class="govuk-grid-row sidebar-with-body" data-module="sticky-element-container">
    <div class="govuk-grid-column-one-quarter-from-desktop contents-list-container">
        <nav aria-label="Contents" class="gem-c-contents-list" data-module="gem-track-click" role="navigation">
    <h2 class="gem-c-contents-list__title">
      Contents
</h2>
    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 1" data-track-category="contentsClicked" data-track-label="#diphtheria-anti-toxin" data-track-options="{&quot;dimension29&quot;:&quot;Diphtheria anti-toxin&quot;}" href="#diphtheria-anti-toxin">Diphtheria anti-toxin</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 2" data-track-category="contentsClicked" data-track-label="#indications" data-track-options="{&quot;dimension29&quot;:&quot;Indications&quot;}" href="#indications">Indications</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 3" data-track-category="contentsClicked" data-track-label="#notes" data-track-options="{&quot;dimension29&quot;:&quot;Notes&quot;}" href="#notes">Notes</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 4" data-track-category="contentsClicked" data-track-label="#dosage" data-track-options="{&quot;dimension29&quot;:&quot;Dosage&quot;}" href="#dosage">Dosage</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 5" data-track-category="contentsClicked" data-track-label="#administration" data-track-options="{&quot;dimension29&quot;:&quot;Administration&quot;}" href="#administration">Administration</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 6" data-track-category="contentsClicked" data-track-label="#sensitivity" data-track-options="{&quot;dimension29&quot;:&quot;Sensitivity testing&quot;}" href="#sensitivity">Sensitivity testing</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 7" data-track-category="contentsClicked" data-track-label="#antimicrobial-therapy" data-track-options="{&quot;dimension29&quot;:&quot;Antimicrobial therapy&quot;}" href="#antimicrobial-therapy">Antimicrobial therapy</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 8" data-track-category="contentsClicked" data-track-label="#pregnancy" data-track-options="{&quot;dimension29&quot;:&quot;Pregnancy&quot;}" href="#pregnancy">Pregnancy</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 9" data-track-category="contentsClicked" data-track-label="#side-effects" data-track-options="{&quot;dimension29&quot;:&quot;Side effects&quot;}" href="#side-effects">Side effects</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 10" data-track-category="contentsClicked" data-track-label="#storage" data-track-options="{&quot;dimension29&quot;:&quot;Storage&quot;}" href="#storage">Storage</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 11" data-track-category="contentsClicked" data-track-label="#acknowledgements" data-track-options="{&quot;dimension29&quot;:&quot;Acknowledgements&quot;}" href="#acknowledgements">Acknowledgements</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 12" data-track-category="contentsClicked" data-track-label="#references" data-track-options="{&quot;dimension29&quot;:&quot;References&quot;}" href="#references">References</a>

        </li>
    </ol>
</nav>
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
    </div>

  <div class="print-wrapper">
    <div class="print-meta-data">
      <p>
  <img class="print-meta-data-licence" src="/assets/government-frontend/open-government-licence-min-93b6a51b518ff99714a1aa2a7d2162735c155ec3cb073c75fb88b2a332fa83d3.png">
</p>
<p>
  © Crown copyright 2022
</p>
<p>
  This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit <a href="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3">nationalarchives.gov.uk/doc/open-government-licence/version/3</a> or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: <a href="mailto:psi@nationalarchives.gov.uk">psi@nationalarchives.gov.uk</a>.
</p>
<p>
  Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
</p>
<p>
  This publication is available at https://www.gov.uk/government/publications/immunoglobulin-when-to-use/diphtheria-anti-toxin-clinical-guidance-issued-may-2022
</p>


    </div>
  </div>

  <div class="main-content-container">
    <div class="gem-c-govspeak-html-publication">
  
<div class="gem-c-govspeak govuk-govspeak " data-module="govspeak">
    
    
      <div class="govspeak">
<h2>Diphtheria anti-toxin</h2>

<p>Before the introduction of diphtheria anti-toxin (<abbr title="diphtheria anti-toxin">DAT</abbr>), mortality rates for clinical diphtheria frequently exceeded 50%. One clinical trial found mortality of 3.3% in patients treated with <abbr title="diphtheria anti-toxin">DAT</abbr> compared with 12.2% in untreated patients<a class="govuk-link" href="#ref1"><sup>[1]</sup></a>.</p>

<p>Early treatment with <abbr title="diphtheria anti-toxin">DAT</abbr> is critical as protection is inversely related to duration of clinical illness preceding administration.</p>

<p>Treatment for probable and confirmed diphtheria cases should be discussed with an infectious diseases clinician – if the patient has a classic respiratory diphtheria presentation, then there is no need to wait for laboratory confirmation of a toxigenic strain before administering <abbr title="diphtheria anti-toxin">DAT</abbr>.</p>

<p><abbr title="diphtheria anti-toxin">DAT</abbr> is based on a horse serum and anaphylaxis occurs more commonly than with human immunoglobulin products. However, from our experience in England of treating patients with <abbr title="diphtheria anti-toxin">DAT</abbr>, anaphylaxis is very rare.</p>

<p>A single diphtheria anti-toxin (equine) product is currently being supplied in the UK.</p>

<p>Diphtheria anti-toxin (<abbr title="diphtheria anti-toxin">DAT</abbr>) manufactured by Butantan Institute (Instituo Butanan) in 10ml ampoules containing 10,000 IU per ampoule (at least 1,000 IU <abbr title="diphtheria anti-toxin">DAT</abbr> per ml).</p>

<h2>Indications</h2>

<p><abbr title="diphtheria anti-toxin">DAT</abbr> indications are for treatment of:</p>

<ul>
  <li>suspected diphtheria cases<sup>*</sup>
</li>
  <li>confirmed infections, where clinically appropriate, due to toxigenic Corynebacteria ulcerans or C. diphtheria</li>
</ul>

<p><sup>*</sup> as defined in <a class="govuk-link" href="https://www.gov.uk/government/publications/diphtheria-public-health-control-and-management-in-england-and-wales">national guidelines</a></p>

<h2>Notes</h2>

<p>Diphtheria anti-toxin should not be used for diphtheria prophylaxis.</p>

<p>Contacts should be given diphtheria-containing vaccine and antibiotic prophylaxis <a class="govuk-link" href="https://www.gov.uk/government/publications/diphtheria-public-health-control-and-management-in-england-and-wales">in line with national guidelines</a>.</p>

<p>Treatment should proceed as soon as possible, as the effectiveness of <abbr title="diphtheria anti-toxin">DAT</abbr> is strongly related to time since disease onset.</p>

<h2>Dosage</h2>

<p>Dosage for diphtheria anti-toxin is determined by the severity and duration of the disease as shown in the table below. The dose is the same for adults and children, and the number of ampoules required is also shown.</p>

<table>
  <thead>
    <tr>
      <th scope="col">Type of diphtheria</th>
      <th scope="col">Dosage adults and children</th>
      <th scope="col">Number of ampoules (10,000    IU/ampoule)</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Severe diphtheria, for example, extensive membrane or severe oedema (‘bull neck’)</td>
      <td>100,000 IU</td>
      <td>10</td>
    </tr>
    <tr>
      <td>Laryngeal or pharyngeal or nasopharyngeal disease of more than 48 hours</td>
      <td>100,000 IU</td>
      <td>10</td>
    </tr>
    <tr>
      <td>Laryngeal or pharyngeal or nasopharyngeal disease of less than 48 hours</td>
      <td>70,000 IU</td>
      <td>7</td>
    </tr>
    <tr>
      <td>Skin lesions</td>
      <td>40,000 IU</td>
      <td>4</td>
    </tr>
  </tbody>
</table>

<p>The World Health Organization (<abbr title="World Health Organization">WHO</abbr>)<a class="govuk-link" href="#ref2"><sup>[2]</sup></a> states that anti-toxin is of limited value in cutaneous disease. In most cutaneous infections, large-scale toxin absorption is unlikely and therefore the risk of giving anti-toxin is usually considered substantially greater than any benefit. Nevertheless, if the cutaneous ulcer is sufficiently large (that is, more than 2cm squared) and membranous, then anti-toxin may be justified.</p>

<p>Note: this guidance will differ from the dosage instructions in the Summary of Product Characteristics (<abbr title="Summary of Product Characteristics">SmPC</abbr>) distributed with the product. In this instance, this guidance document should be followed.</p>

<div class="call-to-action">
<p>Please read the Administration section carefully prior to giving anti-toxin.</p>
</div>

<h2>Administration</h2>

<h3>Precautions for administration</h3>

<p>Prior to administration, a detailed history should be taken including:</p>

<ul>
  <li>previous administration of equine-derived anti-toxin or immunoglobulins</li>
  <li>documented or known animal allergy, specifically equine (horse) allergy</li>
</ul>

<h3>Route</h3>

<p>The intravenous (<abbr title="intravenous">IV</abbr>) route is the preferred route of administration of <abbr title="diphtheria anti-toxin">DAT</abbr>, especially in severe cases.</p>

<p>The anti-toxin dose should be mixed in 250ml to 500ml of normal saline (that is, sodium chloride 0.9% injection) and administered slowly over 2 to 4 hours, closely monitoring for anaphylaxis.</p>

<h3>Delivery of dose</h3>

<ol>
  <li>
    <p>Perform sensitivity tests if indicated, and desensitisation if necessary.</p>
  </li>
  <li>
    <p>Give the entire treatment dose of anti-toxin <abbr title="intravenous">IV</abbr> in a single administration (except for series of injections needed for desensitisation), unless there is the onset of allergic response. Divided doses are not recommended as this increases risk of sensitivity reactions (see section on side effects). <br><br>However, if in exceptional circumstances, the full dose cannot be given in a single administration, for example, in a small child, the maximum interval between the 2 split doses should not exceed 24 hours. If a divided dose is delayed by 72 hours, sensitivity testing should be carried out. For any divided dose between 24 and 72 hours, administration should proceed with caution.</p>
  </li>
</ol>

<h4>Figure 1. Summary of <abbr title="diphtheria anti-toxin">DAT</abbr> administration according to patient history and sensitivity testing</h4>

<p>See <a class="govuk-link" href="#sensitivity">sensitivity testing section</a> below for further details.</p>

<figure class="image embedded"><div class="img"><img alt="" src="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/image_data/file/149397/DAT_fig_1final.png"></div></figure>

<h2>Sensitivity testing</h2>

<h4>In people with a negative history for animal allergy and no prior exposure to equine-derived immunoglobulin:</h4>

<p>Do not perform sensitivity testing and proceed with a slow <abbr title="intravenous">IV</abbr> infusion of full recommended dose.</p>

<p>The anti-toxin should be mixed in 250ml to 500ml of normal saline and administered slowly with 10% of volume over the first 30 minutes, and the remainder over 2 to 4 hours, with close monitoring for anaphylaxis.</p>

<h4>In patients with a positive history for animal allergy or prior exposure to equine-derived immunoglobulin suggesting increased risk:</h4>

<p>1. Inject ~0.05ml of a 1:100 dilution of the serum (in normal saline) intradermally to cause a ~5mm bleb, and wait 30 minutes.</p>

<p>2. If no evidence of hypersensitivity reaction, repeat intradermal injection using a 1:10 dilution of the serum (in normal saline) and wait 30 minutes.</p>

<p>3. If no evidence of hypersensitivity reaction (erythema, itch), proceed with a slow <abbr title="intravenous">IV</abbr> infusion of full recommended dose. The anti-toxin should be mixed in 250ml to 500ml of normal saline and administered slowly with 10% of volume over the first 30 minutes, and the remainder over 2 to 4 hours, with close monitoring for anaphylaxis.</p>

<p>4. If intradermal testing is positive or equivocal, then the schedule of desensitisation should be followed.
To dilute for intradermal testing, make serial dilutions as follows (see also <a class="govuk-link" href="#intratable">Densensitisation to <abbr title="diphtheria anti-toxin">DAT</abbr> – intravenous route</a> table):</p>

<ul>
  <li>0.1ml of serum + 0.9ml normal saline = 1:10 dilution</li>
  <li>0.1ml of 1:10 dilution + 0.9ml normal saline = 1:100 dilution</li>
</ul>

<p>Recent use of an antihistamine (in last 48 to 72 hours) – including antihistamines present in over-the-counter preparations such as cough remedies – may interfere with the intradermal test. In this case, either seek the advice of a specialist in allergy to undertake screening using a positive (histamine) and negative (saline) control, or follow the desensitisation protocol for someone with a positive intradermal test.</p>

<p>5. Monitor the patient carefully during treatment and ensure facilities for treating anaphylaxis (including 1:1,000 adrenaline for injection) are readily available.</p>

<h3>Desensitisation to <abbr title="diphtheria anti-toxin">DAT</abbr>
</h3>

<p>Patients with positive sensitivity testing to <abbr title="diphtheria anti-toxin">DAT</abbr> or with a previous history of adverse reaction to <abbr title="diphtheria anti-toxin">DAT</abbr> administration (even with a negative or equivocal intradermal test) should undergo desensitization, as shown in the table below. The <abbr title="intravenous">IV</abbr> route is considered safer because it offers better control<a class="govuk-link" href="#ref3"><sup>[3]</sup></a>.</p>

<h3>Desensitization to <abbr title="diphtheria anti-toxin">DAT</abbr> – intravenous route</h3>

<table>
  <thead>
    <tr>
      <th scope="col">Dose number*</th>
      <th scope="col">Dilution    of DAT in normal saline</th>
      <th scope="col">Amount    of injection (ml)</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>1</td>
      <td>1:1,000**</td>
      <td>0.1</td>
    </tr>
    <tr>
      <td>2</td>
      <td>1:1,000</td>
      <td>0.3</td>
    </tr>
    <tr>
      <td>3</td>
      <td>1:1,000</td>
      <td>0.6</td>
    </tr>
    <tr>
      <td>4</td>
      <td>1:100**</td>
      <td>0.1</td>
    </tr>
    <tr>
      <td>5</td>
      <td>1:100</td>
      <td>0.3</td>
    </tr>
    <tr>
      <td>6</td>
      <td>1:100</td>
      <td>0.6</td>
    </tr>
    <tr>
      <td>7</td>
      <td>1:10**</td>
      <td>0.1</td>
    </tr>
    <tr>
      <td>8</td>
      <td>1:10</td>
      <td>0.3</td>
    </tr>
    <tr>
      <td>9</td>
      <td>1:10</td>
      <td>0.6</td>
    </tr>
    <tr>
      <td>10</td>
      <td>undiluted</td>
      <td>0.1</td>
    </tr>
    <tr>
      <td>11</td>
      <td>undiluted</td>
      <td>0.2</td>
    </tr>
    <tr>
      <td>12</td>
      <td>undiluted</td>
      <td>0.6</td>
    </tr>
    <tr>
      <td>13</td>
      <td>undiluted</td>
      <td>1.0</td>
    </tr>
  </tbody>
</table>

<p>*Administer at 15 minute intervals</p>

<p>**1 ml (anti-toxin) + 9.0 ml of saline (sodium chloride 0.9% injection) = 1:10 dilution<br>
1 ml (1:10 dilution) + 9.0 ml of saline = 1:100 dilution<br>
0.1 ml (1:10 dilution) + 9.9 ml saline = 1:1,000 dilution<br>
1 ml (1:100 dilution) + 9 ml saline = 1:1,000 dilution<br></p>

<p>The protection from anaphylaxis afforded by giving <abbr title="diphtheria anti-toxin">DAT</abbr> according to this desensitisation protocol requires that no interruption occur in the sequence of administration of doses. Iif an interruption occurs the protection is lost.</p>

<p>If no hypersensitivity reaction occurs, administer remaining quantity of anti-toxin as above.</p>

<h2>Antimicrobial therapy</h2>

<p>Appropriate antimicrobial agents in full therapeutic dosages should be started <a class="govuk-link" href="https://www.gov.uk/government/publications/diphtheria-public-health-control-and-management-in-england-and-wales">in line with national guidelines</a>.</p>

<h2>Pregnancy</h2>

<p>Diphtheria anti-toxin (equine) should be used cautiously during pregnancy.</p>

<h2>Side effects</h2>

<p>Administration of diphtheria anti-toxin may cause hypersensitivity reactions including anaphylaxis. Reactions occur in individuals previously sensitized to equine anti-toxin or horse proteins either through previous administration on in some other way.</p>

<p>Reactions to the anti-toxin may manifest as an anaphylactic reaction and/or serum sickness. This is why giving the required dose of anti-toxin in a single administration is recommended.</p>

<p>Anaphylaxis usually occurs within 1 to 2 hours of administration. The dose of adrenaline for anaphylaxis in teenagers and adults is 0.5ml of 1:1,000 adrenaline given intramuscularly, every 5 minutes.</p>

<p>In the event of severe anaphylaxis (no response to 2+ intramuscular (<abbr title="intramuscular">IM</abbr>) injections of adrenaline), an adrenaline infusion may be needed – call for specialist support.</p>

<p>Serum sickness can occur in up to 5% of patients according to historic data, usually around 7 to 12 days after the first injection although accelerated reactions have been reported in patients who have previously received equine anti-toxin preparations, with onset within days or even hours.</p>

<p>Symptoms include more generalised erythema, urticaria, itching, and occasionally fever, pain and oedema of the joints and lymph nodes.</p>

<p>Treatment is supportive, with anti-inflammatory preparations and antihistamine to provide symptomatic relief – systemic steroids may be needed in more severe cases.</p>

<h2>Storage</h2>

<p>Store at 2ºC to 8ºC. Once the ampoule is opened, the preparation must be used immediately.</p>

<h2>Acknowledgements</h2>

<p>This guidance was prepared by: Gayatri Amirthalingam, Charlotte Gower, Meera Chand, Kevin Brown, Colin Brown, Mary Ramsay.</p>

<p>For queries relating to this document, please contact <a class="govuk-link" href="mailto:immunisation.lead@phe.gov.uk">immunisation.lead@phe.gov.uk</a></p>

<p>The authors gratefully acknowledge the expert review and advice received from: Dr Paul Turner, Honorary Consultant in Paediatric Allergy and Immunology Imperial College London.</p>

<h2>References</h2>

<p>1. ‘Diphtheria; other corynebacterial and coryneform infections’, in In Topley and Wilson’s principles of bacteriology, virology and immunity (chapter 60). 5th edition. Baltimore, MD: Williams and Wilkins, 1964, pp.1695 –98</p>

<p>2. <abbr title="World Health Organization">WHO</abbr> (1994) Diphtheria. Manual for the management and control of diphtheria in the European Region. <abbr title="World Health Organization">WHO</abbr>, Copenhagen</p>

<p>3. <abbr title="Centers for Disease Control and Prevention">CDC</abbr> (2016) Expanded Access Investigational New Drug (<abbr title="Investigational New Drug">IND</abbr>) Application Protocol: ‘Use of Diphtheria Antitoxin (<abbr title="diphtheria anti-toxin">DAT</abbr>) for Suspected Diphtheria Cases’ <abbr title="Investigational New Drug">IND</abbr> Sponsor: Centers for Disease Control and Prevention (<abbr title="Centers for Disease Control and Prevention">CDC</abbr>) Protocol <abbr title="Centers for Disease Control and Prevention">CDC</abbr> IRB #4167</p>

</div>


</div>
</div>
  </div>

  <div class="sticky-element" data-sticky-element="">
    <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" focusable="false" height="17" viewBox="0 0 13 17" width="13" xmlns="http://www.w3.org/2000/svg">
      <path d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z" fill="currentColor"></path>
    </svg>
    Contents
</a>

    <div class="sticky-element__print-link">
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
    </div>
  </div>
</div>

    </main>